Literature DB >> 2112630

Treatment of acid maltase deficiency with a diet high in branched-chain amino acids.

S Mobarhan1, R L Pintozzi, P Damle, H Friedman.   

Abstract

Acid maltase deficiency in adults is associated with progressive muscle weakness and may effect respiratory muscles resulting in respiratory failure. The biochemical and clinical manifestations of acid maltase deficiency arise from a marked deficiency of the lysosomal enzyme alpha-glucosidase (acid maltase), which normally degrades glycogen to free glucose. In the past few years, high-protein diets have provided an alternative energy source for these patients and resulted in improved muscle strength. Recently, we treated a ventilator-dependent acid maltase-deficient patient with a general diet supplemented with branched-chain amino acids. Branched-chain amino acids are the principal amino acids involved in muscle protein synthesis and utilization. While on this diet, the patient had improvement of respiratory function and muscle strength and was able to be weaned from the ventilator during the day. In addition to his nutritional status, levels of serum branched-chain amino acids, showed improvement within 2 months after the diet started. This diet shows potential advantages over a high-protein diet without supplemented branched-chain amino acids for the treatment of acid maltase deficiency. These include theoretical sparing of amino acids required for muscle protein synthesis by providing higher concentrations of postprandial branched-chain amino acids in the circulation. Also, the liquid formula would be better tolerated by a ventilator-dependent or debilitated patient rather than a high-protein general diet. Further experience with branched-chain amino acid formulas will be needed to substantiate their efficacy in the treatment of acid maltase deficiency.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2112630     DOI: 10.1177/0148607190014002210

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  6 in total

Review 1.  The natural course of non-classic Pompe's disease; a review of 225 published cases.

Authors:  Léon P F Winkel; Marloes L C Hagemans; Pieter A van Doorn; M Christa B Loonen; Wim J C Hop; Arnold J J Reuser; Ans T van der Ploeg
Journal:  J Neurol       Date:  2005-08       Impact factor: 4.849

2.  Fatigue: an important feature of late-onset Pompe disease.

Authors:  Marloes L C Hagemans; Sabine P M van Schie; A Cecile J W Janssens; Pieter A van Doorn; Arnold J J Reuser; Ans T van der Ploeg
Journal:  J Neurol       Date:  2007-03-02       Impact factor: 4.849

Review 3.  Fatigue in neuromuscular disorders: focus on Guillain-Barré syndrome and Pompe disease.

Authors:  J M de Vries; M L C Hagemans; J B J Bussmann; A T van der Ploeg; P A van Doorn
Journal:  Cell Mol Life Sci       Date:  2010-03       Impact factor: 9.261

4.  Efficacy of multidisciplinary approach in the treatment of two cases of nonclassical infantile glycogenosis type II.

Authors:  B Bembi; G Ciana; C Martini; A Benettoni; A Gombacci; M Deganuto; M G Pittis
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

5.  Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: consensus recommendations from an expert group.

Authors:  Fatma Al Jasmi; Mohammed Al Jumah; Fatimah Alqarni; Nouriya Al-Sanna'a; Fawziah Al-Sharif; Saeed Bohlega; Edward J Cupler; Waseem Fathalla; Mohamed A Hamdan; Nawal Makhseed; Shahriar Nafissi; Yalda Nilipour; Laila Selim; Nuri Shembesh; Rawda Sunbul; Seyed Hassan Tonekaboni
Journal:  BMC Neurol       Date:  2015-10-15       Impact factor: 2.474

6.  Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease.

Authors:  Jason Wang; Chris J Zhou; Alastair Khodabukus; Sabrina Tran; Sang-Oh Han; Aaron L Carlson; Lauran Madden; Priya S Kishnani; Dwight D Koeberl; Nenad Bursac
Journal:  Commun Biol       Date:  2021-05-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.